

Section 1. Stable Ischemic Heart Disease Without Prior CABG

Appropriate Use Score (1-9)									
ONE VESSEL DISEASE									
No proximal LAD or proximal left dominant LCX involvement									
Indication	Asymptomatic		Ischemic Symptoms						
	Not on AA therapy or with AA therapy		Not on AA Therapy		On 1 AA Drug (BB preferred)		On ≥2 AA Drugs		
	PCI	CABG	PCI	CABG	PCI	CABG	PCI	CABG	
1. • Low-risk findings on noninvasive testing	R (2)	R (1)	R (3)	R (2)	M (4)	R (3)	A (7)	M (5)	
2. • Intermediate or high risk findings on noninvasive testing	M (4)	R (3)	M (5)	M (4)	M (6)	M (4)	A (8)	M (6)	
3. • No stress test performed or, if performed, the results are indeterminant • FFR≤0.80*	M (4)	R (2)	M (5)	R (3)	M (6)	M (4)	A (8)	M (6)	
Proximal LAD or proximal left dominant LCX Involvement present									
4. • Low-risk findings on noninvasive testing	M (4)	R (3)	M (4)	M (4)	M (5)	M (5)	A (7)	A (7)	
5. • Intermediate or high risk findings on noninvasive testing	M (5)	M (5)	M (6)	M (6)	A (7)	A (7)	A (8)	A (8)	
6. • No stress test performed or, if performed, the results are indeterminant • FFR≤0.80	M (5)	M (5)	M (6)	M (6)	M (6)	M (6)	A (8)	A (7)	
TWO VESSEL DISEASE									
No proximal LAD involvement									
7. • Low-risk findings on noninvasive testing	R (3)	R (2)	M (4)	R (3)	M (5)	M (4)	A (7)	M (6)	
8. • Intermediate or high risk findings on noninvasive testing	M (5)	M (4)	M (6)	M (5)	A (7)	M (6)	A (8)	A (7)	
9. • No stress test performed or, if performed, the results are indeterminant • FFR≤0.80* in both vessels	M (5)	M (4)	M (6)	M (4)	A (7)	M (5)	A (8)	A (7)	
Proximal LAD involvement and no diabetes present									
10. • Low-risk findings on noninvasive testing	M (4)	M (4)	M (5)	M (5)	M (6)	M (6)	A (7)	A (7)	
11. • Intermediate or high risk findings on noninvasive testing	M (6)	M (6)	A (7)	A (7)	A (7)	A (7)	A (8)	A (8)	
12. • No stress test performed or, if performed, the results are indeterminant • FFR≤0.80 in both vessels	M (6)	M (6)	M (6)	M (6)	A (7)	A (7)	A (8)	A (8)	
Proximal LAD involvement with diabetes present									
13. • Low-risk findings on noninvasive testing	M (4)	M (5)	M (4)	M (6)	M (6)	A (7)	A (7)	A (8)	
14. • Intermediate or high risk findings on noninvasive testing	M (5)	A (7)	M (6)	A (7)	A (7)	A (8)	A (8)	A (9)	
15. • No stress test performed or, if performed, the results are indeterminant • FFR≤0.80 in both vessels*	M (5)	M (6)	M (6)	A (7)	A (7)	A (8)	A (7)	A (8)	
THREE VESSEL DISEASE									
Low disease complexity (e.g. focal stenoses, SYNTAX ≤22)									
16. • Low-risk findings on noninvasive testing • No diabetes	M (4)	M (5)	M (5)	M (5)	M (6)	M (6)	A (7)	A (7)	
17. • Intermediate or high risk findings on noninvasive testing • No diabetes	M (6)	A (7)	A (7)	A (7)	A (7)	A (8)	A (8)	A (8)	
18. • Low-risk findings on noninvasive testing • Diabetes present	M (4)	M (6)	M (5)	M (6)	M (6)	A (7)	A (7)	A (8)	
19. • Intermediate or high risk findings on noninvasive testing • Diabetes present	M (6)	A (7)	M (6)	A (8)	A (7)	A (8)	A (7)	A (9)	
Intermediate or high disease complexity (e.g. multiple features of complexity as noted above, SYNTAX >22)									
20. • Low-risk findings on noninvasive testing • No diabetes	M (4)	M (6)	M (4)	A (7)	M (5)	A (7)	M (6)	A (8)	
21. • Intermediate or high risk findings on noninvasive testing • No diabetes	M (5)	A (7)	M (6)	A (7)	M (6)	A (8)	M (6)	A (9)	
22. • Low-risk findings on noninvasive testing • Diabetes present	M (4)	A (7)	M (4)	A (7)	M (5)	A (8)	M (6)	A (9)	
23. • Intermediate or high risk findings on noninvasive testing • Diabetes present	M (4)	A (8)	M (5)	A (8)	M (5)	A (8)	M (6)	A (9)	
LEFT MAIN CORONARY ARTERY STENOSIS									
24. • Isolated LMCA disease • Ostial or mid shaft stenosis	M (6)	A (8)	A (7)	A (8)	A (7)	A (9)	A (7)	A (9)	
25. • Isolated LMCA disease • Bifurcation involvement	M (5)	A (8)	M (5)	A (8)	M (5)	A (9)	M (6)	A (9)	
26. • LMCA disease • Ostial or midshaft stenosis • Concurrent multivessel disease • Low disease burden (e.g.1-2 additional focal stenoses, SYNTAX score≤22)	M (6)	A (8)	M (6)	A (9)	A (7)	A (9)	A (7)	A (9)	
27. • Ostial or midshaft stenosis • Concurrent multivessel disease • Intermediate or high disease burden (e.g.1-2 additional bifurcation stenosis, long stenoses, SYNTAX score >22).	M (4)	A (9)	M (4)	A (9)	M (4)	A (9)	M (4)	A (9)	
28. • LMCA disease • Bifurcation involvement • Low disease burden in other vessels (e.g. 1-2 additional focal stenosis, SYNTAX score ≤22)	M (4)	A (8)	M (5)	A (8)	M (5)	A (9)	M (6)	A (9)	
29. • LMCA disease • Bifurcation involvement • Intermediate or high disease burden in other vessels (e.g.1-2 additional bifurcation stenosis, long stenoses, SYNTAX score >22)	R (3)	A (8)	R (3)	A (9)	R (3)	A (9)	R (3)	A (9)	

*Instantaneous wave-free ratio measurements with appropriate normal ranges may be substituted for FFR. The number in parenthesis next to the rating reflects the median score for that indication.

• Abbreviations: A = Appropriate; AA = antianginal; BB = beta-blockers; CABG = coronary artery bypass graft; FFR = fractional flow reserve; LAD = left anterior descending coronary artery; LCX = left circumflex artery; M = May Be Appropriate; PCI = percutaneous coronary intervention; R = Rarely Appropriate.

Section 2. Stable Ischemic Heart Disease With Prior CABG

IMA TO LAD PATENT AND WITHOUT SIGNIFICANT STENOSES									
Indication	Asymptomatic		Ischemic Symptoms						
	Not on AA therapy or with AA therapy		Not on AA Therapy		On 1 AA Drug (BB preferred)		On ≥2 AA Drugs		
	PCI	CABG	PCI	CABG	PCI	CABG	PCI	CABG	
Stenosis supplying one territory disease (bypass graft or native artery) to territory other than anterior									
30. • Low-risk findings on noninvasive testing	R (3)	R (1)	R (3)	R (2)	M (6)	R (3)	A (7)	M (4)	
31. • Intermediate or high risk findings on noninvasive testing	M (5)	R (3)	M (5)	R (3)	A (7)	M (4)	A (8)	M (5)	
32. • No stress test performed or, if performed, the results are indeterminant • FFR of stenosis ≤ 0.80*	M (4)	R (3)	M (4)	R (3)	M (6)	M (4)	A (8)	M (5)	
Stenoses supplying two territories (bypass graft or native artery, either two separate vessels or sequential graft supplying 2 territories) not including anterior territory									
33. • Low-risk findings on noninvasive testing	R (3)	R (2)	M (4)	R (3)	M (6)	R (3)	A (7)	M (5)	
34. • Intermediate or high risk findings on noninvasive testing	M (5)	R (3)	M (5)	M (4)	A (7)	M (5)	A (8)	M (6)	
IMA TO LAD NOT PATENT									
Stenosis supplying one territory disease (bypass graft or native artery) – Anterior (LAD) territory									
35. • Low-risk findings on noninvasive testing	M (4)	R (3)	M (5)	R (3)	M (6)	M (4)	A (7)	M (5)	
36. • Intermediate or high risk findings on noninvasive testing	M (6)	M (4)	M (6)	M (4)	A (7)	M (5)	A (8)	M (6)	
37. • No stress test performed or, if performed, the results are indeterminant • FFR of stenosis ≤ 0.80*	M (5)	M (4)	M (6)	M (4)	A (7)	M (5)	A (8)	M (6)	
Stenoses supplying two territories (Bypass graft or native artery, either two separate vessels or sequential graft supplying 2 territories) LAD plus one other territory									
38. • Low-risk findings on noninvasive testing	M (5)	M (4)	M (6)	M (4)	A (7)	M (5)	A (7)	M (6)	
39. • Intermediate or high risk findings on noninvasive testing	M (6)	M (5)	A (7)	M (6)	A (7)	A (7)	A (8)	A (8)	
Stenoses supplying three territories (Bypass graft or native arteries, either separate vessels, sequential grafts or combination thereof) LAD plus two other territories									
40. • Low-risk findings on noninvasive testing	M (5)	M (5)	M (6)	M (5)	M (6)	M (6)	A (7)	A (7)	
41. • Intermediate or high risk findings on noninvasive testing	A (7)	A (7)	A (7)	A (7)	A (7)	A (7)	A (8)	A (8)	

Section 3. Stable Ischemic Heart Disease undergoing procedures for which coronary revascularization may be considered

STABLE ISCHEMIC HEART DISEASE UNDERGOING PROCEDURES FOR WHICH CORONARY REVASCLARIZATION MAY BE CONSIDERED									
Patients undergoing renal transplantation, no diabetes									
Indication	Asymptomatic		Ischemic Symptoms						
	Not on AA therapy or with AA therapy		Not on AA Therapy		On 1 AA Drug (BB preferred)		On ≥2 AA Drugs		
	PCI	CABG	PCI	CABG	PCI	CABG	PCI	CABG	
42. • 1 or 2 vessel CAD, no proximal LAD involvement with low risk non-invasive findings	R (3)	R (2)	M (4)	R (3)	M (6)	M (4)	A (7)	M (5)	
43. • 1 or 2 vessel CAD, no proximal LAD involvement with intermediate or high risk non-invasive findings	M (5)	M (4)	M (6)	M (4)	A (7)	M (5)	A (8)	M (6)	
44. • 1 or 2 vessel CAD, including proximal LAD with low risk non-invasive findings	M (5)	M (4)	M (6)	M (5)	M (6)	M (6)	A (8)	A (7)	
45. • 1 or 2 vessel CAD, including proximal LAD with intermediate or high risk non-invasive findings	M (6)	M (6)	A (7)	A (7)	A (7)	A (7)	A (8)	A (8)	
46. • Left main and/or 3 vessel disease; intermediate or high risk non-invasive findings (e.g. SYNTAX ≤22)	M (6)	A (7)	A (7)	A (7)	A (7)	A (7)	A (8)	A (8)	
47. • Left main and/or 3 vessel disease; intermediate or high risk non-invasive findings (e.g. SYNTAX >22)	M (5)	A (7)	M (6)	A (8)	M (6)	A (8)	M (6)	A (9)	
Patients undergoing renal transplantation, diabetes present									
48. • 1 or 2 vessel CAD, no proximal LAD involvement with low risk non-invasive findings	R (3)	R (3)	M (4)	R (3)	M (5)	M (4)	A (7)	M (6)	
49. • 1 or 2 vessel CAD, no proximal LAD involvement with intermediate or high risk non-invasive findings	M (5)	M (4)	M (5)	M (4)	M (6)	M (5)	A (7)	A (7)	
50. • 1 or 2 vessel CAD, including proximal LAD with low risk non-invasive findings	M (5)	M (5)	M (5)	M (6)	M (5)	A (7)	A (7)	A (7)	
51. • 1 or 2 vessel CAD, including proximal LAD with intermediate or high risk non-invasive findings	M (6)	M (6)	M (6)	A (7)	M (6)	A (7)	A (7)	A (8)	
52. • Left main and/or 3 vessel disease; intermediate or high risk non-invasive findings (e.g. SYNTAX ≤22)	M (6)	A (8)	M (6)	A (8)	M (6)	A (8)	A (7)	A (9)	
53. • Left main and/or 3 vessel disease; intermediate or high risk non-invasive findings (e.g. SYNTAX >22)	M (5)	A (8)	M (5)	A (8)	M (5)	A (9)	M (5)	A (9)	
Patient who will undergo a percutaneous valve procedure (TAVR, Mitra-clip, others)									
54. • 1 or 2 vessel CAD, no proximal LAD involvement with low risk non-invasive findings	M (4)		M (4)		M (6)		A (8)		
55. • 1 or 2 vessel CAD, no proximal LAD involvement with intermediate or high risk non-invasive findings	A (7)		A (7)		A (7)		A (8)		
56. • 1 or 2 vessel CAD, including proximal LAD with low risk non-invasive findings	M (6)		M (6)		A (7)		A (8)		
57. • 1 or 2 vessel CAD, including proximal LAD with intermediate or high risk non-invasive findings	A (7)		A (7)		A (8)		A (9)		
58. • Left main and/or 3 vessel disease; intermediate or high risk non-invasive findings (e.g. SYNTAX ≤22)	A (8)		A (8)		A (8)		A (9)		
59. • Left main and/or 3 vessel disease; intermediate or high risk non-invasive findings (e.g. SYNTAX >22)	A (7)		A (7)		A (8)		A (8)		

M = May Be Appropriate; PCI = percutaneous coronary intervention; R = Rarely Appropriate.